Ascendiant Capital Markets Forecasts RenovoRx Q3 Earnings

RenovoRx, Inc. (NASDAQ:RNXT) – Equities research analysts at Ascendiant Capital Markets decreased their Q3 2026 EPS estimates for shares of RenovoRx in a research note issued on Sunday, May 31st. Ascendiant Capital Markets analyst E. Woo now anticipates that the company will earn ($0.07) per share for the quarter, down from their previous forecast of ($0.06). Ascendiant Capital Markets has a “Buy” rating and a $14.00 price target on the stock. The consensus estimate for RenovoRx’s current full-year earnings is ($0.30) per share. Ascendiant Capital Markets also issued estimates for RenovoRx’s FY2026 earnings at ($0.29) EPS, Q1 2027 earnings at ($0.07) EPS, Q2 2027 earnings at ($0.07) EPS, Q3 2027 earnings at ($0.07) EPS, Q4 2027 earnings at ($0.06) EPS and FY2027 earnings at ($0.27) EPS.

Several other equities research analysts also recently weighed in on RNXT. HC Wainwright reaffirmed a “buy” rating and set a $3.00 target price on shares of RenovoRx in a research note on Wednesday, April 8th. Wall Street Zen downgraded shares of RenovoRx from a “hold” rating to a “strong sell” rating in a research report on Saturday, April 4th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, RenovoRx presently has a consensus rating of “Moderate Buy” and an average price target of $8.50.

RenovoRx Stock Down 0.5%

Shares of RNXT opened at $0.91 on Thursday. RenovoRx has a fifty-two week low of $0.70 and a fifty-two week high of $1.45. The firm’s 50 day moving average price is $0.93 and its 200 day moving average price is $0.93. The company has a market cap of $40.84 million, a P/E ratio of -2.74 and a beta of 1.01.

RenovoRx (NASDAQ:RNXT) last announced its earnings results on Thursday, May 14th. The company reported ($0.08) earnings per share for the quarter, hitting the consensus estimate of ($0.08). RenovoRx had a negative net margin of 823.98% and a negative return on equity of 135.03%. The firm had revenue of $0.56 million for the quarter, compared to the consensus estimate of $0.47 million.

Institutional Investors Weigh In On RenovoRx

A number of large investors have recently modified their holdings of RNXT. XTX Topco Ltd increased its position in shares of RenovoRx by 58.6% in the 4th quarter. XTX Topco Ltd now owns 50,140 shares of the company’s stock valued at $42,000 after purchasing an additional 18,525 shares during the last quarter. Northwestern Mutual Wealth Management Co. acquired a new position in shares of RenovoRx in the 2nd quarter valued at $98,000. Citadel Advisors LLC acquired a new position in shares of RenovoRx in the 3rd quarter valued at $154,000. Wealthspire Advisors LLC acquired a new position in shares of RenovoRx in the 4th quarter valued at $212,000. Finally, Geode Capital Management LLC boosted its holdings in shares of RenovoRx by 9.9% in the 2nd quarter. Geode Capital Management LLC now owns 353,603 shares of the company’s stock valued at $467,000 after buying an additional 31,730 shares in the last quarter. 3.10% of the stock is owned by hedge funds and other institutional investors.

RenovoRx Company Profile

RenovoRx, Inc is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.

RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors.